Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 PK and Safety Study in Healthy Chinese Adults
NCT06111547Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zasocitinib in plaque psoriasis (3 arms), sponsored by Takeda. Primary endpoints: Area Under the Concentration Time Curve From Time 0 to the Time t at Day 1, Area Under the Concentration-time Curve From Time 0 To Infinity at Day 1 and 3 more. Started Jun 2024; status: completed.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06111547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111547.